Background: Metabolic syndrome is associated with increased risk for both type 2 diabetes
and cardiovascular disease. Development of these pathologies is associated with the disorders of lipid
and lipoprotein metabolism. Dyslipidemia leads to the overproduction of potentially atherogenic lipid
and lipoproteins. Furthermore, there is a decrease in the levels of high-density lipoproteins and an
increase in the levels of remnant and small dense LDL particles.
Conclusion: In the current review, we have discussed the pathophysiology of lipoprotein biosynthesis
and metabolism in the metabolic syndrome. Finally, we describe regulation of lipoprotein metabolism
which may be used as a potential target for treating dyslipidemia in metabolic syndrome.